Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 plus platinum-based chemotherapy as first-line treatment for advanced gallbladder cancer
CTR20250739Phase 2Active
- Sponsor
- Zelgen
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig in gallbladder adenocarcinoma, biliary cancer, sponsored by Zelgen. Started Dec 2025; status: active.
02
Drugs
nilvanstomig
03
Conditions
gallbladder adenocarcinomabiliary cancer
Beyond the preview
Go deeper on CTR20250739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250739.